Literature DB >> 33841628

Exosomes in osteosarcoma research and preclinical practice.

Xiao-Bo Zhang1,2, Rui-Hao Zhang1,2, Xin Su3, Jin Qi1,2, Yi-Cun Hu1,2, Jin-Tao Shi1,2, Kai Zhang1,2, Ke-Ping Wang1,4, Hai-Yu Zhou1,4.   

Abstract

Osteosarcoma (OS) is a rare soft-tissue malignant tumor with high lung metastasis and mortality rates. Preoperative chemotherapy, surgical resection of the lesion and postoperative chemotherapy are still the main treatments for osteosarcoma. The prognosis, however, is poor for patients with nonresectable, primary metastatic or relapsed disease. Recent studies have shown that targeted therapy for OS based on the characteristics of exosomes is very attractive. Exosomes are nanosized extracellular vesicles (EVs) that participate in cell-to-cell communication by transporting biologically active cargo molecules, causing changes in OS cell function and playing important roles in OS disease progression. With the characteristics of secretory cells, exosomes transport cargo (e.g., microRNAs) that can be used to detect the progress of a disease and can serve as markers and/or therapeutic targets for clinical diagnosis of OS. In this review, the roles of exosomes in OS pathogenesis, invasion, metastasis, drug resistance, diagnosis and treatment are summarized. In addition, this article elaborates a series of challenges to overcome before exosomes are applied in clinical practice and provides suggestions based on current evidence for the direction of future research. AJTR
Copyright © 2021.

Entities:  

Keywords:  Osteosarcoma (OS); challenges; exosomes; microRNA (miRNA)

Year:  2021        PMID: 33841628      PMCID: PMC8014357     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  116 in total

1.  Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126.

Authors:  Wei Liu; Linwei Li; Yuluo Rong; Dingfei Qian; Jian Chen; Zheng Zhou; Yongjun Luo; Dongdong Jiang; Lin Cheng; Shujie Zhao; Fanqi Kong; Jiaxing Wang; Zhimin Zhou; Tao Xu; Fangyi Gong; Yifan Huang; Changjiang Gu; Xuan Zhao; Jianling Bai; Feng Wang; Wene Zhao; Le Zhang; Xiaoyan Li; Guoyong Yin; Jin Fan; Weihua Cai
Journal:  Acta Biomater       Date:  2019-12-17       Impact factor: 8.947

Review 2.  An update on chemotherapy for osteosarcoma.

Authors:  Stefano Ferrari; Massimo Serra
Journal:  Expert Opin Pharmacother       Date:  2015-10-29       Impact factor: 3.889

3.  Generation and testing of clinical-grade exosomes for pancreatic cancer.

Authors:  Mayela Mendt; Sushrut Kamerkar; Hikaru Sugimoto; Kathleen M McAndrews; Chia-Chin Wu; Mihai Gagea; Sujuan Yang; Elena V Rodriges Blanko; Qian Peng; Xiaoyan Ma; Joseph R Marszalek; Anirban Maitra; Cassian Yee; Katayoun Rezvani; Elizabeth Shpall; Valerie S LeBleu; Raghu Kalluri
Journal:  JCI Insight       Date:  2018-04-19

4.  A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells.

Authors:  Tonny Lagerweij; Maria Pérez-Lanzón; S Rubina Baglio
Journal:  J Vis Exp       Date:  2018-05-06       Impact factor: 1.355

5.  MicroRNA profiling of serum exosomes in patients with osteosarcoma by high-throughput sequencing.

Authors:  Zhimeng Ye; Zhuojun Zheng; Linrui Peng
Journal:  J Investig Med       Date:  2020-02-13       Impact factor: 2.895

6.  Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?

Authors:  Emanuela Palmerini; Elisa Torricelli; Stefano Cascinu; Michela Pierini; Massimiliano De Paolis; Davide Donati; Marilena Cesari; Alessandra Longhi; Massimo Abate; Anna Paioli; Elisabetta Setola; Stefano Ferrari
Journal:  Pediatr Blood Cancer       Date:  2019-05-06       Impact factor: 3.167

7.  Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations.

Authors:  Myung Soo Kim; Matthew J Haney; Yuling Zhao; Dongfen Yuan; Irina Deygen; Natalia L Klyachko; Alexander V Kabanov; Elena V Batrakova
Journal:  Nanomedicine       Date:  2017-10-02       Impact factor: 5.307

8.  Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model.

Authors:  Aranzazu Villasante; Alessandro Marturano-Kruik; Srikanth R Ambati; Zen Liu; Amandine Godier-Furnemont; Hesam Parsa; Benjamin W Lee; Malcolm A S Moore; Gordana Vunjak-Novakovic
Journal:  Theranostics       Date:  2016-05-21       Impact factor: 11.556

9.  Identification of characteristic gene modules of osteosarcoma using bioinformatics analysis indicates the possible molecular pathogenesis.

Authors:  Hongmin Li; Yangke He; Peng Hao; Pan Liu
Journal:  Mol Med Rep       Date:  2017-02-24       Impact factor: 2.952

10.  A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.

Authors:  Hongxiang Wei; Jinyuan Chen; Shenglin Wang; Feihuan Fu; Xia Zhu; Chaoyang Wu; Zhoujie Liu; Guangxian Zhong; Jianhua Lin
Journal:  Int J Nanomedicine       Date:  2019-11-01
View more
  4 in total

Review 1.  The basic characteristics of extracellular vesicles and their potential application in bone sarcomas.

Authors:  Shenglong Li
Journal:  J Nanobiotechnology       Date:  2021-09-17       Impact factor: 10.435

2.  Secretory defects in pediatric osteosarcoma result from downregulation of selective COPII coatomer proteins.

Authors:  Rachael K Wood; Ashley R Flory; Melissa J Mann; Lindsay J Talbot; Linda M Hendershot
Journal:  iScience       Date:  2022-03-17

Review 3.  Review of the Role of Mesenchymal Stem Cells and Exosomes Derived from Mesenchymal Stem Cells in the Treatment of Orthopedic Disease.

Authors:  Sihang Ren; Chenchao Wang; Shu Guo
Journal:  Med Sci Monit       Date:  2022-04-28

Review 4.  Role of extracellular vesicles in osteosarcoma.

Authors:  Qifan Yang; Jing Liu; Bo Wu; Xinyu Wang; Ye Jiang; Dong Zhu
Journal:  Int J Med Sci       Date:  2022-07-04       Impact factor: 3.642

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.